Keep Pressure BioSciences Inc (OTCMKTS:PBIO) Stock On Your Watchlist
When it comes to choosing companies to follow from the healthcare industry it is often a good idea to look into companies which are innovative in nature. There are plenty of options to look into for investors at this point in time and one of those is the Pressure BioSciences Inc (OTCMKTS:PBIO) stock.
The company is one of the leading players in developing and selling new age pressure-based solutions that could then be used in the wider life sciences industries. The company is well-known for deploying its patented Pressure Cycling Technology or PCT for developing its products that help with the treatment of a variety of health conditions.
However, in order to have a clearer idea about a company, it is also necessary for investors to ensure that they take a look at recent developments and then make up their minds.
Shatters Preconceived Nanoemulsion Stability, Performance, and Production Limits
Back in December 22 last year there was a major development when Pressure BioSciences announced that it had used its Ultra Shear Technology platform had been used for processing CBD derived from hemp.
The CBD that had been produced by the platform was not only of high quality but also displayed nanoemulsions of CBD oil in water that were water-soluble. In this context, it ought to be remembered that CBD has become one of the more popular products from the cannabis industry and has now found widespread application in the healthcare sector.
It can be used for treating PTSD, anxiety, chronic and inflammatory pain among others. Hence, the possibility of Pressure BioSciences getting into this business could prove to be a long-term boost for the company.
Q3 Financial Results Maintain Solid 2021 YTD Growth
Earlier on in 2021 in November the company had announced its financial results for the third fiscal quarter that had ended on September 30, 2021.
The revenues came in at $518000 and that was 3% lower than the revenues that had been generated in the prior-year period. On the other hand, the instrument sales stood at $274000, which was significantly lower than the $312700 that had been generated in the prior-year period. It now remains to be seen if the Pressure BioSciences stock can manage to garner the attention of investors or not.